TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36278971

Group type: EXPERIMENTAL
Intervention: Lower target for oxygen saturation (90%; goal range, 88 to 92%)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Intermediate target for oxygen saturation (94%; goal range, 92 to 96%)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Higher target for oxygen saturation (98%; goal range, 96 to 100%)
Number of subjects: 2541
Study: 34182983

Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet, physical activity, stress level, alcohol and nicotine consumption) after cancer diagnosis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Increased fruit and vegetable consumption
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reduced meat consumption
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Change in physical activity
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reduction in perceived stress level
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Smoking cessation or reduction
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reduction in alcohol consumption
Number of subjects: 141
Study: 36036836

Group type: EXPERIMENTAL
Intervention: Non-invasive Er:YAG laser with SMOOTH mode (NightLase)
Number of subjects: 0
Study: 34160321

Group type: EXPERIMENTAL
Intervention: Covered endovascular reconstruction of aortic bifurcation (CERAB)
Number of subjects: 116
Study: 35168640

Group type: EXPERIMENTAL
Intervention: Community health advisor (CHA) intervention with a 6-week CRC educational program including an initial face-to-face meeting followed by 5 weeks of calls and texts, along with a brochure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brochure only (control group).
Number of subjects: 0
Study: 32540793

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 450

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 450

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 450
Study: 35728680

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 29
Study: 32160968

Group type: EXPERIMENTAL
Intervention: Mild-moderate supervised exercise program (IG)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 92
Study: 34894627

Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Curriculum physical education (2 × 60-minute sessions per week)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week) in lower birthweight subgroup
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week) in normal birthweight subgroup
Number of subjects: 99
Study: 33221705

Group type: EXPERIMENTAL
Intervention: Revealed PlGF testing and management guidance
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1006
Study: 32912947

Group type: EXPERIMENTAL
Intervention: Invitation to a telephone-based risk-assessment for a Lung Health Check
Number of subjects: 62980

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62980
Study: 34379607

Group type: EXPERIMENTAL
Intervention: Diet with 1.2g of protein plus high-protein supplement (36g whey protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starch as a placebo
Number of subjects: 0
Study: 34931494

Group type: EXPERIMENTAL
Intervention: BR‐TD‐1001
Number of subjects: 218

Group type: COMPARATOR
Intervention: Td (Td‐pur, GlaxoSmithKline)
Number of subjects: 218
Study: 35963046

Group type: EXPERIMENTAL
Intervention: Telehealth-enhanced interdisciplinary home visits (IN-HOME-PD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (POP controls)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison between IN-HOME-PD and POP controls
Number of subjects: 65
Study: 33483108

Group type: EXPERIMENTAL
Intervention: GPS intervention (community-based and peer-delivered sexual health promotion motivational interviewing-based intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GPS intervention
Number of subjects: 0
Study: 33926540

Group type: EXPERIMENTAL
Intervention: Brief exposure to online text and image‐based messages addressing necessity beliefs and concerns about COVID‐19 vaccination.
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Brief exposure to online text and image‐based messages containing general information about COVID‐19 and COVID‐19 vaccination.
Number of subjects: 1094
Study: 32031088

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20
Study: 36256600

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33537860

Group type: EXPERIMENTAL
Intervention: Machine learning trained on time-frequency acoustic spectra
Number of subjects: 13

Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 13
Study: 32450063

Group type: EXPERIMENTAL
Intervention: Removable rigid dressing (RRD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Elastic bandage (EB)
Number of subjects: 25
Study: 35353887

Group type: EXPERIMENTAL
Intervention: Active stimulation (40-min, 77.5 Hz, 15 mA, one forehead and two mastoid sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active stimulation and Sham stimulation
Number of subjects: 100
Study: 34163159

Group type: EXPERIMENTAL
Intervention: Ivermectin mucoadhesive nanosuspension nasal spray twice daily plus Egyptian protocol for mild COVID-19
Number of subjects: 114

Group type: COMPARATOR
Intervention: Egyptian protocol for mild COVID-19 only
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ivermectin mucoadhesive nanosuspension nasal spray
Number of subjects: 114
Study: 32791499

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Verbal education
Number of subjects: 100
Study: 35144924

Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR, 900 mg ×3, 300 mg thereafter)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Combined anifrolumab (BR and IR)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab basic regimen (BR, 300 mg)
Number of subjects: 147
Study: 33944577

Group type: EXPERIMENTAL
Intervention: Conidial suspension (10^5 ml^-1) from a 15-day-old culture of F. ipomoeae
Number of subjects: 22

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 22
Study: 32705833

Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion applied 2 hours after chemotherapy for 20 min each time, once daily for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received intravenous injection of Tropisetron (5 mg) 1 h before chemotherapy
Number of subjects: 60
Study: 36721509

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg daily for five days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ceftriaxone 1 gram daily and azithromycin 500 mg daily for 5-7 days
Number of subjects: 151
Study: 35687107

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 9583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9583
Study: 34265173

Group type: EXPERIMENTAL
Intervention: Lacosamide monotherapy (200-600 mg/day)
Number of subjects: 106
Study: 36444879

Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT) 3 days a week for 6 weeks in addition to a home-based exercise programme
Number of subjects: 40
Study: 33993600

Group type: EXPERIMENTAL
Intervention: Core Maternity Waiting Home (MWH) model
Number of subjects: 40
Study: 32353635

Group type: EXPERIMENTAL
Intervention: Decision‐Rule Based Treatment (DR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sequential Treatment (SEQ)
Number of subjects: 30
Study: 36323718

Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standing group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Green spaces
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Outdoor urban space
Number of subjects: 42
Study: 33828171

Group type: EXPERIMENTAL
Intervention: Trunk Compliance Index (TCI) measured using anthropometrically-matched, suddenly-applied pulling perturbations to the trunk segment across three planes of motion (antero-posterior, medio-lateral, and rotational).
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Receiver Operator Characteristic (ROC) analysis of TCI.
Number of subjects: 49
Study: 35705150

Group type: EXPERIMENTAL
Intervention: Liberal fluid intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluid restriction (1500ml/day)
Number of subjects: 0
Study: 33582490

Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (high difficulty)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (low difficulty)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (neutral cues)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (withdrawal cues)
Number of subjects: 484
Study: 32275367

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electroacupuncture at specified acupoints, continuous wave, 2 Hz, 30 min, 3 times a week for 1 month, 4 courses total)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle interventions (exercise and diet guidance)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40
Study: 35523242

Group type: EXPERIMENTAL
Intervention: IMB model intervention group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard OAB management control group (n = 30)
Number of subjects: 60
Study: 32941794

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery
Number of subjects: 266

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 266
Study: 33245796

Group type: COMPARATOR
Intervention: Evogliptin (5 mg single dose) in patients with mild hepatic impairment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evogliptin (5 mg single dose) in patients with moderate hepatic impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evogliptin (5 mg single dose)
Number of subjects: 0
Study: 32714084

Group type: EXPERIMENTAL
Intervention: Intermittent repeated doses of dexamethasone (15 mg total)
Number of subjects: 42

Group type: COMPARATOR
Intervention: One-time 5-mg dose of dexamethasone
Number of subjects: 42
Study: 35941548

Group type: EXPERIMENTAL
Intervention: Transforaminal injection of Magnesium sulphate with steroids
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Transforaminal injection of Ozone with steroids
Number of subjects: 135

Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 135
Study: 33632940

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 49
Study: 33226116

Group type: EXPERIMENTAL
Intervention: Inverse probability of treatment weights (IPTWs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size calculations with design effects
Number of subjects: 0
Study: 32463163

Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fascial closure
Number of subjects: 50
Study: 33768522

Group type: EXPERIMENTAL
Intervention: Banafine®
Number of subjects: 30
Study: 32118788

Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (TS) at temperatures 46°C to 47°C (hot pain) and 7°C to 8°C (cold pain)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (TS) at temperatures 40°C to 41°C (hot) and 20°C to 21°C (cold)
Number of subjects: 16
Study: 35513022

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33863842

Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Rheumatologist-led care (RLC)
Number of subjects: 224
Study: 34799440

Group type: EXPERIMENTAL
Intervention: NHANES-III equation with 'North Indian and Pakistani' conversion factor
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Global Lung Function Initiative (GLI) equation for 'other or mixed ethnicities'
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Recent equation derived from a western Indian population
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Older and smaller survey of Karachi residents
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: FEV1/FVC ratio (<lower limit of normality)
Number of subjects: 1724
Study: 33960667

Group type: EXPERIMENTAL
Intervention: Soft silicone dressings (a contact layer and/or foam)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-adhesive dressings
Number of subjects: 126
Study: 33653634

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (RARC) after previous prostate surgery (PPS)
Number of subjects: 220
Study: 70648026

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q12h
Number of subjects: 797

Group type: COMPARATOR
Intervention: Vancomycin/aztreonam (V/A) 1 g/1 g q12h
Number of subjects: 797
Study: 33264236

Group type: EXPERIMENTAL
Intervention: LED flashlights in Risk Group 2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LED flashlights in Risk Group 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All evaluated flashlights
Number of subjects: 6
Study: 32023373

Group type: EXPERIMENTAL
Intervention: Lower threshold treatment (glucose concentration <36 mg/dL)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Traditional threshold treatment (glucose concentration <47 mg/dL)
Number of subjects: 689
Study: 616841087

Group type: COMPARATOR
Intervention: 0 g fiber from SCF/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 g fiber from SCF/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 g fiber from SCF/d
Number of subjects: 0
Study: 35065291

Group type: EXPERIMENTAL
Intervention: Opioid-free pain management pathway (OF)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional opioid-containing pain management pathway (OC)
Number of subjects: 67
Study: 34635058

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis group (experimental group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (non-atopic patients)
Number of subjects: 61
Study: 32273542

Group type: EXPERIMENTAL
Intervention: Frequency of consumption of sugary drinks
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Season of birth
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Father's educational level
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Mother's educational level
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Type of housing
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Passive smoking at home
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Sleeping hours during weekends
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Students' educational level
Number of subjects: 1370
Study: 35247729

Group type: EXPERIMENTAL
Intervention: Neurofeedback-guided kinesthetic motor imagery training (MI-NF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active control visual imagery (VI)
Number of subjects: 44
Study: 34719909

Group type: EXPERIMENTAL
Intervention: Active treatment with portable magnet therapy device ALMAG+ (Almag Active)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 77
Study: 32925287

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 36350354

Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin
Number of subjects: 388

Group type: COMPARATOR
Intervention: Standard dosing of beta-lactam antibiotics and ciprofloxacin
Number of subjects: 388
Study: 33175638

Group type: EXPERIMENTAL
Intervention: Basic information with additional detail about timeline of HPV infection (Group 2)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Basic information with a diagram (Group 3)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Basic information (Group 1)
Number of subjects: 585
Study: 34566873

Group type: EXPERIMENTAL
Intervention: Active FGMS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham FGMS
Number of subjects: 34
Study: 34003436

Group type: EXPERIMENTAL
Intervention: Sleep duration < 6 hours
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Sleep duration 6-7 hours
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: > 7 hours of sleep
Number of subjects: 505
Study: 33766423

Group type: EXPERIMENTAL
Intervention: Educational follow-up with the motivational interview technique (phone calls during weeks 1, 3, 6, and 9)
Number of subjects: 80
Study: 32874115

Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Running Speed Increase
Number of subjects: 15
Study: 35143022

Group type: EXPERIMENTAL
Intervention: Risk score based on predictive model
Number of subjects: 49750

Group type: EXPERIMENTAL
Intervention: Risk groups derived from risk score
Number of subjects: 49750

Group type: EXPERIMENTAL
Intervention: Baseline comorbidities and treatments
Number of subjects: 49750

Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 49750

Group type: EXPERIMENTAL
Intervention: Drugs increasing risk
Number of subjects: 49750
Study: 33711985

Group type: EXPERIMENTAL
Intervention: Near-peer teaching (NPT) tutor assistance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no NPT tutor)
Number of subjects: 60
Study: 32399253

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: RCI
Number of subjects: 270
Study: 35655225

Group type: EXPERIMENTAL
Intervention: Jian-Pi Huo-Xue granule (JPHX)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: JPHX
Number of subjects: 84
Study: 33301017

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every 6 hours for 5 to 7 days
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every 6 hours for 5 to 7 days with enteral 50 μg of fludrocortisone daily for 7 days
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Treat by SAPS II strategy
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Optimal individual model strategy
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Placebo or usual care
Number of subjects: 2548
Study: 36449096

Group type: EXPERIMENTAL
Intervention: l-arginine (1000 mg capsule three times a day for 1 month)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 34039574

Group type: EXPERIMENTAL
Intervention: Fundamental nursing care protocol
Number of subjects: 840

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 840
Study: 33160382

Group type: EXPERIMENTAL
Intervention: HIIT (5 × 1 min at 80–95% maximal heart rate on cycle ergometers, 2×/week for 12 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 65

Group type: COMPARATOR
Intervention: CON (inactive control group)
Number of subjects: 65
Study: 35946487

Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care (ciKMC)
Number of subjects: 550
Study: 34157093

Group type: EXPERIMENTAL
Intervention: omidubicel
Number of subjects: 125

Group type: COMPARATOR
Intervention: standard UCBT
Number of subjects: 125
Study: 32668408

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 15
Study: 33455931

Group type: EXPERIMENTAL
Intervention: Technology-enabled rehabilitation package (exercise program via Physitrack app, health-coaching via video calls, physical activity tracker with goal setting, Goniometer app for TKR)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Technology-enabled rehabilitation package
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual postsurgical care
Number of subjects: 204
Study: 32085716

Group type: EXPERIMENTAL
Intervention: Atmiyata intervention (community-based interventions for mental health, including evidence-based counseling)
Number of subjects: 1520000

Group type: EXPERIMENTAL
Intervention: Atmiyata intervention
Number of subjects: 1520000
Study: 32357128

Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based McKenzie therapy (TBMT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Clinic-based McKenzie therapy (CBMT)
Number of subjects: 47
Study: 36203394

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) patches, 5-week supply provided to half of the participants.
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRT patches
Number of subjects: 0
Study: 32918306

Group type: COMPARATOR
Intervention: Biopsy A (no SWE guidance)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Biopsy B (SWE guidance, rigid areas)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Biopsy C (SWE guidance, less rigid areas)
Number of subjects: 58
Study: 35748897

Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: SVM
Number of subjects: 298

Group type: COMPARATOR
Intervention: DT
Number of subjects: 298

Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 298
Study: 33591324

Group type: EXPERIMENTAL
Intervention: RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2])
Number of subjects: 421

Group type: COMPARATOR
Intervention: R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2])
Number of subjects: 421
Study: 32379236

Group type: EXPERIMENTAL
Intervention: BFR WIDE
Number of subjects: 14

Group type: COMPARATOR
Intervention: NO-BFR
Number of subjects: 14